ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: HER2 Mutation-Related Tumors|HER2 Amplified Solid Tumors
Interventions: DRUG: ARX788
Sponsor: Ambrx, Inc.